康缘药业
(600557)
| 流通市值：72.81亿 | | | 总市值：73.23亿 |
| 流通股本：5.66亿 | | | 总股本：5.69亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,094,172,093.81 | 2,195,076,101.94 | 1,816,857,563.46 | 2,072,277,809.7 |
| 应收票据及应收账款 | 525,924,489.91 | 525,920,722.65 | 652,710,094.78 | 654,057,500.26 |
| 应收账款 | 525,924,489.91 | 525,920,722.65 | 652,710,094.78 | 654,057,500.26 |
| 应收款项融资 | 219,347,096.58 | 174,623,132.05 | 335,483,569.74 | 334,485,002.87 |
| 预付款项 | 35,194,399.24 | 26,562,911.57 | 44,363,418.68 | 41,925,235.1 |
| 其他应收款合计 | 4,416,279.65 | 6,325,142.86 | 2,842,561.9 | 12,055,048.14 |
| 存货 | 515,373,930.8 | 540,269,821.74 | 546,132,223.92 | 503,529,046.01 |
| 其他流动资产 | 71,315,315.11 | 87,127,580.55 | 6,681,775.79 | 72,206,990.79 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 3,515,743,605.1 | 3,595,905,413.36 | 3,730,071,208.27 | 3,900,536,632.87 |
| 非流动资产: | | | | |
| 长期股权投资 | 4,126,567.57 | 4,126,567.57 | 4,114,497.17 | 4,114,497.17 |
| 其他非流动金融资产 | 8,195,658.61 | 11,210,107.4 | 11,210,107.4 | 11,210,107.4 |
| 固定资产 | 2,263,344,673.05 | 2,278,707,657.81 | 2,266,913,709.32 | 2,216,612,851.7 |
| 在建工程 | 533,396,074.51 | 472,805,540.4 | 318,779,434.99 | 283,845,544.57 |
| 无形资产 | 166,462,108.32 | 171,460,213.98 | 170,354,732.17 | 176,823,021.73 |
| 开发支出 | 188,334,900.9 | 187,992,816.15 | 181,500,752.87 | 177,592,549.86 |
| 商誉 | 58,988,858.14 | 58,988,858.14 | 58,988,858.14 | 58,988,858.14 |
| 长期待摊费用 | 14,571,182.48 | 15,849,914.7 | 12,066,595.33 | 12,845,479.9 |
| 递延所得税资产 | 46,295,367.01 | 45,313,093.18 | 43,037,864.13 | 47,122,929.59 |
| 其他非流动资产 | 85,319,097.28 | 64,402,198.69 | 105,701,791.85 | 164,555,125.94 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,369,034,487.87 | 3,310,856,968.02 | 3,172,668,343.37 | 3,153,710,966 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 6,884,778,092.97 | 6,906,762,381.38 | 6,902,739,551.64 | 7,054,247,598.87 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 257,872,794.67 | 226,872,983.31 | 145,272,571.69 | 230,926,714.92 |
| 其中：应付票据 | 103,905,270.62 | 37,698,661.68 | - | - |
| 应付账款 | 153,967,524.05 | 189,174,321.63 | 145,272,571.69 | 230,926,714.92 |
| 合同负债 | 24,292,139.61 | 25,455,210.81 | 15,610,563.69 | 18,553,584.87 |
| 应付职工薪酬 | 7,817,858.76 | 29,058,146.1 | 18,082,362.06 | 12,486,551.7 |
| 应交税费 | 35,421,632.45 | 34,988,075.94 | 75,789,914.18 | 52,899,975.06 |
| 其他应付款合计 | 1,601,079,799.21 | 1,725,154,638.53 | 1,179,373,526.81 | 1,243,042,997.71 |
| 其他流动负债 | 3,150,549.36 | 2,951,853.2 | 2,022,985.6 | 2,396,945.14 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,929,634,774.06 | 2,044,480,907.89 | 1,436,151,924.03 | 1,560,306,769.4 |
| 非流动负债: | | | | |
| 长期应付款 | 1,925,490 | 1,925,490 | 1,925,490 | 1,925,490 |
| 递延收益 | 162,574,952.29 | 155,265,492.05 | 128,918,547.37 | 156,508,335.2 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 164,500,442.29 | 157,190,982.05 | 130,844,037.37 | 158,433,825.2 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 2,094,135,216.35 | 2,201,671,889.94 | 1,566,995,961.4 | 1,718,740,594.6 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 569,459,106 | 581,797,452 | 581,797,452 | 581,797,452 |
| 资本公积 | - | - | 92,956,075.65 | 92,956,075.65 |
| 减:库存股 | 26,068,966 | 211,978,588.9 | 210,094,122.29 | 120,002,291.37 |
| 盈余公积 | - | 76,254,078.46 | 292,813,413.08 | 292,813,413.08 |
| 未分配利润 | 4,054,598,654.86 | 4,068,502,873.09 | 4,392,678,207.64 | 4,300,956,522.94 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 4,597,988,794.86 | 4,514,575,814.65 | 5,150,151,026.08 | 5,148,521,172.3 |
| 少数股东权益 | 192,654,081.76 | 190,514,676.79 | 185,592,564.16 | 186,985,831.97 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 4,790,642,876.62 | 4,705,090,491.44 | 5,335,743,590.24 | 5,335,507,004.27 |
| 负债和股东权益合计 | 6,884,778,092.97 | 6,906,762,381.38 | 6,902,739,551.64 | 7,054,247,598.87 |
| 公告日期 | 2025-04-30 | 2025-04-03 | 2024-10-31 | 2024-07-27 |
| 审计意见(境内) | | 标准无保留意见 | | |